跳至主要内容
临床试验/EUCTR2018-003022-89-GR
EUCTR2018-003022-89-GR进行中(未招募)1 期

GUT-DERIVED INCRETIN HORMONES IN THE PATHOPHYSIOLOGY OF TYPE 1 DIABETES MELLITUS; EFFECT OF METFORMIN TREATMENT (THE INCREDIBLE-ME TRIAL) - INCREDIBLE ME

HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS0 个研究点目标入组 44 人开始时间: 2019年10月2日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Age = 18 years
  • T1DM (Diagnosis of diabetes before the age of 35 years and insulin use within 1 year from diagnosis)
  • Treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 44
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 44

排除标准

  • Acute or within the last 3 months cardiovascular disease
  • NYHA stage 3 or 4 heart failure
  • Uncontrolled angina
  • Liver failure [AST>135 IU/L or ALT>129IU/L (3 x the upper normal limit)]
  • Kidney failure or GFR<60 ml/min/1.73m2
  • Gastrointestinal disease or gastroparesis
  • Prior diagnosis of cancer within 2 years
  • Other medication that affect glucose metabolism within the last 3 months (metformin, SGLT2, GLP-1 analogues, amylin analogues, systemic glucocorticoids)
  • Untreated or uncontrolled thyroid disease
  • Pregnancy or breastfeeding
  • Alcohol consumption > 2-drinks per day or other substance abuse.

研究者

相似试验